Understanding the Mechanism of Pathological alpha-Synuclein Transmission

了解病理性 α-突触核蛋白传播的机制

基本信息

  • 批准号:
    10647710
  • 负责人:
  • 金额:
    $ 40.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-17 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

α-Synucleinopathies are a subset of neurodegenerative diseases, including Parkinson's disease (PD), dementia with Lewy Bodies (DLB) and multiple system atrophy (MSA) (1), which are characterized by abnormal accumulation of misfolded α-synuclein (α-syn) protein in neurons or glial cells. Emerging evidence suggests that the cell-to-cell transmission of pathological α-syn substantially cause neurodegeneration. However, the molecular mechanism of α-syn transmission is poorly understood. We have identified three transmembrane proteins that strongly bind with α-syn PFF: (i) lymphocyte activation gene-3 (LAG3), (ii) amyloid β precursor-like protein 1 (APLP1), and (iii) neurexin 1-β. LAG3 is an essential receptor, mediating internalization of α-syn PFF; however, substantial α-syn PFF binds to LAG3-/- (knockout) neurons, suggesting that a unidentified candidate(s) (e.g. APLP1) binds with pathologic α-syn, and facilitate the internalization. In this proposal, we hypothesize: (i) APLP1 is an essential receptor, that mediates α-syn transmission; (ii) APLP1-LAG3 complex synergistically mediates α-syn transmission; (iii) depletion of APLP1, LAG3, or APLP1- LAG3 complex, can reduce α-syn-induced neurodegeneration of α-syn transgenic mice. Accordingly, experiments are proposed to characterize the roles of APLP1, LAG3 and the AL complex in mediating the pathogenesis of α-synucleinopathies, in cell-to-cell transmission models and the α-syn transgenic mouse model. Experiments in two mice models with α-synucleinopathies, will be complemented by studies in cells and cell-free experiments, thus allowing the deciphering of each spreading step in the interaction of APLP1, LAG3, or the AL complex with pathologic α-syn. The successful completion of these studies will greatly enhance our understanding of the molecular mechanisms of α-syn cell-to-cell transmission via receptors, by: (i) identifying APLP1 as a novel receptor that mediates α-syn spreading, (ii) understanding the synergistic effect of the AL complex on mediating binding and internalization of α-syn PFF, (iii) providing essential preliminary evaluation of anti-LAG3 antibody as a potential therapeutic agent against PD and related α-synucleinopathies, and (iv) understanding the roles of APLP1, LAG3, and the AL complex in mediating neurodegeneration of α-syn transgenic mice.
α-突触核蛋白病是神经退行性疾病的一个子集,包括帕金森病(PD), 路易体痴呆(DLB)和多系统萎缩(MSA)(1),其特征在于: 神经元或神经胶质细胞中错误折叠的α-突触核蛋白(α-syn)蛋白的异常积累。新出现的证据 表明病理性α-syn的细胞-细胞传递实质上导致神经变性。 然而,α-syn传输的分子机制知之甚少。我们已经确定了三个 与α-syn PFF强结合的跨膜蛋白:(i)淋巴细胞活化基因-3(LAG 3),(ii) 淀粉样β受体样蛋白1(APLP 1),和(iii)neurexin 1-β。LAG 3是一种重要的受体,介导 α-syn PFF的内化;然而,大量的α-syn PFF与LAG 3-/-(敲除)神经元结合,表明 未鉴定的候选物(例如APLP 1)与病理性α-syn结合,并促进内化。 在这个提议中,我们假设:(i)APLP 1是一个重要的受体,介导α-syn传递;(ii) APLP 1-LAG 3复合物协同介导α-syn传递;(iii)APLP 1、LAG 3或APLP 1-LAG 3的耗竭 LAG 3复合物可减轻α-syn转基因小鼠的神经退行性变。因此,委员会认为, 实验提出了表征APLP 1,LAG 3和AL复合物在介导的作用, 细胞间传播模型和α-syn转基因中α-突触核蛋白病的发病机制 小鼠模型在患有α-突触核蛋白病的两种小鼠模型中进行的实验将通过以下研究进行补充: 细胞和无细胞实验,从而允许破译的相互作用中的每个扩散步骤, APLP 1、LAG 3或AL与病理性α-syn的复合物。这些研究的成功完成将 大大提高了我们对α-syn细胞间传递的分子机制的理解, 受体,通过:(i)确定APLP 1作为一种新的受体,介导α-syn传播,(ii)了解 AL复合物对介导α-syn PFF的结合和内化的协同作用,(iii)提供 抗LAG 3抗体作为PD及相关疾病潜在治疗药物的基本初步评价 α-突触核蛋白病,以及(iv)了解APLP 1,LAG 3和AL复合物在介导 α-syn转基因小鼠的神经变性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiaobo Mao其他文献

Xiaobo Mao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiaobo Mao', 18)}}的其他基金

α-Synuclein strain properties are associated with diagnosis of and progression to Parkinson's disease with dementia
α-突触核蛋白菌株特性与帕金森病伴痴呆的诊断和进展相关
  • 批准号:
    10369767
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Chemical Fingerprints of Cognitive Impairment-related alpha-Synuclein Strains using 3D Small Molecule Microarray and Related Therapeutic Application
使用 3D 小分子微阵列的认知障碍相关 α-突触核蛋白菌株的化学指纹及相关治疗应用
  • 批准号:
    10360139
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
阿尔茨海默病中病理性 Tau 原纤维神经元间传递和神经炎症的机制
  • 批准号:
    10626135
  • 财政年份:
    2021
  • 资助金额:
    $ 40.94万
  • 项目类别:
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
阿尔茨海默病中病理性 Tau 原纤维神经元间传递和神经炎症的机制
  • 批准号:
    10277023
  • 财政年份:
    2021
  • 资助金额:
    $ 40.94万
  • 项目类别:
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
阿尔茨海默病中病理性 Tau 原纤维神经元间传递和神经炎症的机制
  • 批准号:
    10461946
  • 财政年份:
    2021
  • 资助金额:
    $ 40.94万
  • 项目类别:
Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein Spreading
异时性血液交换通过调节血浆蛋白对病理性 α 突触核蛋白扩散的调节来抑制 α 突触核蛋白病
  • 批准号:
    10495186
  • 财政年份:
    2021
  • 资助金额:
    $ 40.94万
  • 项目类别:
Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein Spreading
异时性血液交换通过调节血浆蛋白对病理性 α 突触核蛋白扩散的调节来抑制 α 突触核蛋白病
  • 批准号:
    10197457
  • 财政年份:
    2021
  • 资助金额:
    $ 40.94万
  • 项目类别:
Understanding the Mechanism of Pathological alpha-Synuclein Transmission
了解病理性 α-突触核蛋白传播的机制
  • 批准号:
    9816185
  • 财政年份:
    2019
  • 资助金额:
    $ 40.94万
  • 项目类别:
Understanding the Mechanism of Pathological alpha-Synuclein Transmission
了解病理性 α-突触核蛋白传播的机制
  • 批准号:
    10019607
  • 财政年份:
    2019
  • 资助金额:
    $ 40.94万
  • 项目类别:
Understanding the Mechanism of Pathological alpha-Synuclein Transmission
了解病理性 α-突触核蛋白传播的机制
  • 批准号:
    10445274
  • 财政年份:
    2019
  • 资助金额:
    $ 40.94万
  • 项目类别:

相似海外基金

Development of prevention of Alzheimer's disease using transgenic soybean expressing amyloid beta protein
使用表达β淀粉样蛋白的转基因大豆预防阿尔茨海默病的进展
  • 批准号:
    19K07989
  • 财政年份:
    2019
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: Dynamics of surfactant - amyloid-beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂 - 淀粉样蛋白 - β 蛋白相互作用的动力学
  • 批准号:
    1802641
  • 财政年份:
    2018
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Standard Grant
Collaborative Research: Dynamics of surfactant - amyloid-beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂 - 淀粉样蛋白 - β 蛋白相互作用的动力学
  • 批准号:
    1802588
  • 财政年份:
    2018
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Standard Grant
Analysis of a new mechanism to specifically inhibit amyloid-beta protein production
特异性抑制β-淀粉样蛋白产生的新机制分析
  • 批准号:
    18K14883
  • 财政年份:
    2018
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Dynamics of surfactant - amyloid beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂-淀粉样β蛋白相互作用的动力学
  • 批准号:
    1802793
  • 财政年份:
    2018
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Standard Grant
Aggregation of amyloid-beta protein on size-controlled lipid nanoparticles
淀粉样β蛋白在尺寸控制的脂质纳米颗粒上的聚集
  • 批准号:
    16K18860
  • 财政年份:
    2016
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Structure and molecular interactions in aggregation of amyloid beta protein
β淀粉样蛋白聚集的结构和分子相互作用
  • 批准号:
    26860020
  • 财政年份:
    2014
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
A novel therapeutic strategy for Alzheimer's disease based on the promotion of clearance mechanism of amyloid beta protein
基于促进β淀粉样蛋白清除机制的阿尔茨海默病新治疗策略
  • 批准号:
    26670126
  • 财政年份:
    2014
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Amyloid Beta-Protein: Wild Type and Familial Mutant Assembly and Inhibition
β-淀粉样蛋白:野生型和家族突变体的组装和抑制
  • 批准号:
    8728102
  • 财政年份:
    2013
  • 资助金额:
    $ 40.94万
  • 项目类别:
Amyloid Beta-Protein: Wild Type and Familial Mutant Assembly and Inhibition
β-淀粉样蛋白:野生型和家族突变体的组装和抑制
  • 批准号:
    9110110
  • 财政年份:
    2013
  • 资助金额:
    $ 40.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了